Ariel Pablos-Méndez
Director/Board Member at Global Alliance for TB Drug Development
Profile
Ariel Pablos-Méndez has held director positions at the Global Alliance for TB Drug Development and ILiAD Biotechnologies LLC.
Ariel Pablos-Méndez active positions
Companies | Position | Start |
---|---|---|
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Director/Board Member | - |
ILiAD Biotechnologies LLC
ILiAD Biotechnologies LLC BiotechnologyHealth Technology ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
ILiAD Biotechnologies LLC
ILiAD Biotechnologies LLC BiotechnologyHealth Technology ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Ariel Pablos-Méndez